Psoriatic Disease
FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older
The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.
Stress may be associated with increased risk of psoriasis among men
Low stress resilience in men may be linked to an increased risk for developing psoriasis or psoriatic arthritis, according to a study.
IL-17 inhibitors may break TNFi ‘glass ceiling’ in psoriatic arthritis prescribing
Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.
IL-17, IL-23 inhibitors may not reactivate tuberculosis in patients with psoriasis
Interleukin-17 and IL-23 inhibitors do not increase the risk for tuberculosis reactivation among patients with psoriatic disease who have a latent tuberculosis infection, according to a retrospective study.
Difficult-to-treat psoriatic arthritis 'not all about the therapies'
DESTIN, Fla. — The course of difficult-to-treat psoriatic arthritis can be significantly impacted by a host of factors beyond choice of therapy, according to data presented at the Congress of Clinical Rheumatology East annual meeting.
Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes
Patients with psoriatic arthritis who receive deucravacitinib report significant improvements in mental health, pain, fatigue and other outcomes vs. placebo, according to data published in Arthritis Care & Research.
New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure
Rheumatologists should turn to biologics as usual treatment in patients with psoriatic arthritis who demonstrate an inadequate response to methotrexate, according to new EULAR recommendations.
ARCA biopharma, Oruka Therapeutics enter merger agreement
ARCA biopharma and Oruka Therapeutics have entered into a definitive merger agreement and will now operate under Oruka Therapeutics, ARCA announced in a press release.
Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis
Patients with psoriatic arthritis in Canada face “substantial burden and unmet need” for improved treatments, as nearly 75% fail to achieve minimal disease activity within 6 months of starting advanced therapy, according to data.
Guselkumab improves work productivity, overall health over 2 years in psoriatic arthritis
Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.